Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.
about
Continued lamivudine for adults with lamivudine-resistant chronic hepatitis B virus infectionInterferon for people with lamivudine-resistant chronic hepatitis B virus infectionAdefovir dipivoxil for adults with lamivudine-resistant chronic hepatitis B virus infectionAntiviral agents for hepatitis B virus-related cirrhosisPrevention of Hepatitis B reactivation in the setting of immunosuppressionManagement of hepatitis B reactivation in immunosuppressed patients: An update on current recommendationsBetter plans and more powerful evidence are needed in the research and treatment of chronic hepatitis B in China.Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinomaAntiviral Therapy of Liver Cirrhosis Related to Hepatitis B Virus InfectionUpdate on Hepatitis B Virus Infection: Focus on TreatmentHepatitis B and Hepatitis C Reactivation in the Biologic EraAnti-HBV Drugs: Progress, Unmet Needs, and New HopePrediction of fibrosis progression in chronic viral hepatitisManagement of patients with hepatitis B who require immunosuppressive therapySystematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection?Hepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawalManagement of chronic hepatitis B infection: current treatment guidelines, challenges, and new developmentsManagement of chronic hepatitis B before and after liver transplantationPrevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapyAntiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-AnalysisPotential effects of telbivudine and entecavir on renal function: a systematic review and meta-analysisHepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-ScreenedThe efficacy and safety of Nucleos(t)ide analogues in patients with spontaneous acute exacerbation of chronic hepatitis B: a systematic review and meta-analysisAssociation of preexisting drug-resistance mutations and treatment failure in hepatitis B patientsEmergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in ChinaAnalysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countriesRisk prediction models for hepatocellular carcinoma in different populations.The Gamma-Glutamyl-Transpeptidase to Platelet Ratio Does not Show Advantages than APRI and Fib-4 in Diagnosing Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis B: A Retrospective Cohort Study in ChinaAsian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Recent advances in micro/nanotechnologies for global control of hepatitis B infectionCurrent hepatitis B treatment guidelines and future research directions.Helicobacter pylori infection influences the severity of thrombocytopenia and its treatment response in chronic hepatitis B patients with compensatory cirrhosis: A multicenter, observational study.Hepatitis B infection is associated with an increased incidence of thrombocytopenia in healthy adults without cirrhosis.Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmissionHepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.Protective effect of an improved immunization practice of mother-to-infant transmission of hepatitis B virus and risk factors associated with immunoprophylaxis failureQuantitative hepatitis B core antibody level is associated with inflammatory activity in treatment-naïve chronic hepatitis B patients.Alpha-interferon treatment in hepatitis BEfficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study.Optimization therapy for the treatment of chronic hepatitis B
P2860
Q24185958-FB5B6740-2B76-43BA-A3D2-8DEA7DB0AF39Q24185973-EFC1566E-6BF1-4966-935A-8D80BFBF8F93Q24187530-5C594AAB-373A-4B8C-947D-8067A721C281Q24200681-643A5BC2-4D01-46F8-A852-605E91E205DCQ26747023-A734AAE8-9065-43C3-BCA6-A34025A8B3D8Q26752690-CFD24F49-E883-4E2B-927A-84985E4D79B1Q26765290-8D33D65E-655D-4815-81BD-773A2E5520D8Q26773251-F0588FBF-BA4A-42DE-8B56-2D7C56A61DABQ26781962-1510221D-838B-403E-A5D7-95216170C104Q26781990-30132B2B-59CF-46B8-B31F-66405C28F441Q26781993-30873F44-E054-438D-AE0E-9E62CCF05B45Q26782742-28A965D1-77F7-4324-AC29-7ECA296AF825Q26823671-B903FCAD-20EF-4672-97DD-606749453F27Q26853490-46FAB856-A2C4-419F-A2EE-88B67F10BD6FQ26865747-8BA78274-67CA-42DB-A026-46A871B2F04CQ26995814-AABACD02-9D30-4977-996D-49948AE414D2Q27008984-BAB74C92-8801-40CD-9AD2-88F2F0488E2EQ27024831-4BE34992-A98F-4EEE-A53F-3C3D6AA342FEQ28070090-955D22CD-1783-484E-912F-95AF278610C3Q28074579-983A53A4-06C5-4A49-8936-A2448B288A47Q28074863-D237A61B-904B-4FD1-BF33-7185A2E5C8DBQ28076703-8FF518CD-5C28-4EE9-B0FA-186796F06E0CQ28533788-1070539B-95B5-4B75-A8A4-CBC5DC7DD8B2Q28535003-AD6AE741-2038-4809-B138-6245CBB2E10FQ28547345-E13832F8-FDBE-4ADF-9B24-BD934FDA034CQ28830093-3DA0C8B5-DF46-4022-9119-733C820C798BQ30383460-3B8A2AFC-9751-401E-89DB-CCD8DF8497FDQ30383724-AC4C66D6-6F65-47FC-9437-FF1592ECFF1BQ30391932-74EC71C5-82C7-43B6-A4BB-08D3AC91EF96Q30394611-C0143C66-F16B-4ECE-AF9D-9079F2D45CA4Q30487002-B50B04CC-59EE-4521-A6B0-1E898A2EDF75Q33425621-7770F30D-07F9-4A53-98FC-0C40033529FEQ33436901-D03A8DCA-5E6F-49A1-8212-4E111A646F8AQ33560668-8C1BFDAB-AAE5-4E3F-B44A-2BA94561297BQ33564294-2771E706-4A4E-4C94-9153-878C4E106721Q33590502-83FEAC11-134F-4665-9C7B-0D8BA27E228EQ33590508-C43E8F35-AFA7-405F-95D3-35D0919D8B4EQ33592755-57DF2A2B-76B3-4895-B99E-D9EC9A75BEA0Q33608997-CB40DB25-41C0-47EC-AE48-03AF032C3741Q33626813-CFA36768-90EE-47D8-9886-111A2946119E
P2860
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Asian-Pacific consensus statem ...... ic hepatitis B: a 2012 update.
@ast
Asian-Pacific consensus statem ...... ic hepatitis B: a 2012 update.
@en
type
label
Asian-Pacific consensus statem ...... ic hepatitis B: a 2012 update.
@ast
Asian-Pacific consensus statem ...... ic hepatitis B: a 2012 update.
@en
prefLabel
Asian-Pacific consensus statem ...... ic hepatitis B: a 2012 update.
@ast
Asian-Pacific consensus statem ...... ic hepatitis B: a 2012 update.
@en
P2093
P1476
Asian-Pacific consensus statem ...... ic hepatitis B: a 2012 update.
@en
P2093
Deepak Amarapurkar
Dong-Jin Suh
Graham Cooksley
Henry Lik Yuen Chan
Jin-Lin Hou
Jose D Sollano
Kwang-Hyub Han
Laurentius A Lesmana
Masao Omata
P2888
P304
P356
10.1007/S12072-012-9365-4
P577
2012-05-17T00:00:00Z